ArticleFrontiers in medicine2026
Predicting propofol requirements in advanced gastrointestinal endoscopy: a validated model incorporating age and comorbidity index.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Propofol requirements during advanced gastrointestinal endoscopy vary substantially among patients with multimorbidity, and the influence of comorbidity burden remains incompletely characterized. This study aimed to evaluate the association between Charlson Comorbidity Index (CCI), age-adjusted CCI (ACCI), and propofol requirement, and to develop a model for individualized sedation. Methods: This retrospective cohort study included 1,555 adult patients undergoing advanced gastrointestinal endoscopy (primarily endoscopic retrograde cholangiopancreatography and endoscopic ultrasonography) under bispectral index (BIS)-guided target-controlled infusion (TCI) propofol sedation at a tertiary referral center between 2017 and 2023. The primary outcome was the lean body mass (LBM)-adjusted propofol infusion rate. Patients were classified into higher- and lower-propofol requirement groups for logistic regression analyses, and sensitivity analyses were performed using the continuous outcome variable. Model discrimination was evaluated using the area under the receiver operating characteristic curve (AUC) with internal split-sample validation. Results: Older age, male sex, longer procedure duration, and higher CCI were independently associated with a lower probability of higher propofol requirement in multivariable analysis. Sensitivity analyses using the continuous LBM-adjusted propofol infusion rate yielded consistent findings. The model demonstrated good discrimination in both the training cohort (AUC 0.831, 95% CI 0.808-0.853) and validation cohort (AUC 0.841, 95% CI 0.780-0.882). Conclusions: Older age, male sex, and higher comorbidity burden were independently associated with lower relative propofol requirements during advanced gastrointestinal endoscopy under BIS-guided TCI sedation. The proposed model demonstrated acceptable discrimination; however, external validation is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.